Solventum (NYSE:SOLV) Raised to “Buy” at Wall Street Zen

Solventum (NYSE:SOLV) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.

A number of other brokerages have also recently weighed in on SOLV. BMO Capital Markets began coverage on Solventum in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target for the company. KeyCorp increased their price objective on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. BTIG Research raised their target price on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Piper Sandler lifted their target price on shares of Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, UBS Group lifted their target price on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Solventum presently has an average rating of “Moderate Buy” and a consensus price target of $92.80.

Solventum Price Performance

Shares of NYSE:SOLV opened at $87.43 on Friday. The business’s 50 day simple moving average is $85.15 and its 200-day simple moving average is $76.58. The firm has a market capitalization of $14.88 billion, a price-to-earnings ratio of 10.69, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.Solventum’s quarterly revenue was up 2.2% on a year-over-year basis. During the same period last year, the business posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities analysts forecast that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Trading of Solventum

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd purchased a new position in Solventum in the second quarter valued at about $3,402,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum in the second quarter worth about $150,066,000. SG Americas Securities LLC grew its stake in shares of Solventum by 38.4% in the first quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock valued at $8,467,000 after buying an additional 35,982 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Solventum in the second quarter valued at about $61,460,000. Finally, First Trust Advisors LP raised its holdings in shares of Solventum by 57.4% during the 1st quarter. First Trust Advisors LP now owns 334,441 shares of the company’s stock valued at $21,839,000 after buying an additional 121,989 shares during the period.

Solventum Company Profile

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.